Perceptual filling-in is a process that compensates the discontinuity in signals of interest by restoring the missing information based on the spatially or temporally adjacent context. Although perceptual filling-in is well documented in vision, hearing and touch, to date little has been researched about the perceptual filling-in in thermal modality. Thermal referral is a phenomenon that shares phenomenological similarities with perceptual filling-in. When observers touched three stimulators simultaneously with D2, D3 and D4 but only the outer two stimulators were cooled or heated, the central (neutral) stimulator was also perceived to be cold or warm. However, when D3 was held above the central stimulator, this illusory thermal sensation disappeared, indicating that thermal sensations can only be filled-in when concurrent tactile input was presented. To clarify whether the resulting sensation of thermal referral possesses similar characteristics as those resulted from typical perceptual filling-in, we investigated the intensity perception under thermal referral; more specifically we examined the uniformity of the resulting sensation and measured its apparent intensity as a function of the physical intensity applied to D2 and D4. We found that the resulting sensation was uniform, but its apparent intensity was always lower than the physical intensity applied, indicating this uniformity was not created by interpolating the thermal changes experienced directly at D2 and D4. Instead, the thermal changes experienced at D2 and D4 were integrated and redistributed to all three fingers in contact, so that a uniform sensation with lower apparent intensity was perceived. Our findings suggest that thermal referral is a process of perceptually integrating and redistributing thermal sensations to the apparent loci of concurrent tactile stimulation and support the idea that perceptual filling-in is a consequence of neural computation instead of the brain's ignoring an absence. Genetic incompatibility mice (Genic mice) made by crossing two normal wild-derived mouse strains, BLG2 and KJR, show defective growth, microphthalmus, lethality and neurological defects such as tremor and ataxia. Because the parental strains never show such defects, Genic mice is etiologically caused by genetic incompatibility and consider as a model of sporadic neurological disease. We identified one of the causative loci, Genetic incompatibility 1 (Genic1) on Chromosome 13 and have narrowed the locus down to approximately 1.6Mbp genomic interval, where about 40 genes are reported in the database of NCBI build37.1.Congenic mice carrying KJR homozygous allele at Genic1 in the background of BLG2 (BLG2-Genic1 K/K ) showed hypomyelination characterized by most axons which are enclosed by no myelin and thinner myelin layers in spinal cord and optic nerve. Expression microarray and qPCR using neonatal spinal cord indicate that the genes related to maturation and myelination of oligodendrocyte (OLs) were decreased in BLG2-Genic1 K/K mice. The genomic interval of Genic1 has peculiarly duplicated structure composed of a few genes which are not directly related to the myelination or maturation of OLs. Comparative genome hybridization array (CGH array) showed Genic1 has copy number varaiants (CNVs) of the repetitive genes. Interestingly, BLG2-Genic1 K/K show high expression of a retrotransposon and interferoninducible genes which might be a response to unregulated double strand RNAs. These phenomena could be signs of abnormal epigenetic state like as perturbation of the genome or chromatin structure, which is recently reported in interbreed crossing of plants. The polyglutamine (polyQ) diseases are a group of inherited neurodegenerative diseases caused by an expanded polyQ stretch within disease-causing proteins. The expanded polyQ proteins are thought to exert neurotoxicity via misfolding and aggregation, and their eventual deposition as inclusion bodies within neurons, and hence misfolding/aggregation of polyQ proteins are ideal therapeutic targets. We previously identified the aggregate inhibitor QBP1 (PolyQ Binding Peptide 1), and showed that expression of QBP1 by a transgenic approach inhibits neurodegeneration in Drosophila polyQ disease models. Furthermore, molecular chaperones such as Hsp40 and Hsp70, which prevent protein misfolding and assist protein refolding, have also been shown to exert therapeutic effects on polyQ disease models upon their expression. However, for such therapeutic molecules to actually be useful as a therapy, they must be expressed throughout the brain using an exogenously delivered transgene. In this study, we therefore investigated the therapeutic effect of adeno-associated virus type 5 (AAV5)-mediated gene expression of aggregate inhibitors on a polyQ disease mouse model. Injection of AAV5 into the mouse striatum resulted in widespread and long-term expression of the transgenes in the brain. Injection of AAV5-QBP1 into the striatum of polyQ disease mice at 1 week of age resulted in suppression of inclusion body formation in infected neurons. Most importantly, injection of AAV5-Hsp40 resulted in suppression of inclusion body formation as well as amelioration of neurological phenotypes of polyQ disease mice, including open-field activity, rearing, grip strength, weight, and lifespan. Our results indicate the potential of AAV5-mediated expression of aggregate inhibitors as a therapeutic strategy for the currently untreatable polyQ diseases. DNA repair defends against naturally occurring or disease-associated DNA damage during the long lifespan of neurons, and is implicated in polyglutamine disease pathology. Recently, we found that the reduction of nuclear HMGB1 protein level in the nucleus associates with DNA double-strand break (DSB)-mediated neuronal damage in Huntington's disease (HD). However, the questions remain, whether genomic double-strand DNA is actually cleaved especially in neurons, whether DNA repair is affected in polyQ diseases, and which molecules mediate the DNA repair dysfunction. Here we report that mutant huntingtin (Htt) expression in neurons causes double strand breaks (DSBs) of genomic DNA and mutant Htt further promotes DSBs by impairing DNA repair. We identify Ku70, a component of the DNA damage-repair complex, as a mediator of the DNA repair dysfunction in mutant Htt-expressing neurons. Mutant Htt interacts with Ku70, impairs DNA-dependent protein kinase (DNA-PK) function in non-homologous end joining (NHEJ), and consequently increases DSBs accumulation. Expression of exogenous Ku70 rescues abnormal behavior and pathological phenotypes in the R6/2 mouse model of Huntington's disease. These results collectively suggest that Ku70 is a critical regulator of DNA damage in HD pathology.
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